Alemtuzumab gets two bites of the cherry. #MSBlog #MSResearch
“The following press release from Genzyme indicates that the FDA will reassess alemtuzumab via a standard route rather than via an appeal process. Maybe MSers in the US will get access to this drug before the end of the year.”
“The following press release from Genzyme indicates that the FDA will reassess alemtuzumab via a standard route rather than via an appeal process. Maybe MSers in the US will get access to this drug before the end of the year.”
This is wonderful news as it allows the FDA to save face. I think the chances of Lemtrada getting a US license must now be very high. If it went to appeal the chances would have been much lower. Good news for people with MSers.